Table 3 |
||||||
|
Diagonal linear discriminant analysis of NSCLC cell lines |
||||||
|
Predicted sensitivity to EGFR TKI |
||||||
|
|
||||||
|
Cell Line |
Experimental Sensitivity to EGFR TKI (erlotinib) |
Prediction based on analysis of mutational status alone (Exons 18–21) |
Genomic signature/DLDA |
|||
|
|
||||||
|
10-genes |
50-genes |
180-genes |
||||
|
|
||||||
|
Training |
A549 |
No |
√ |
√* |
√ |
√ |
|
UKY-29 |
No |
√ |
√ |
√ |
||
|
H1650 |
Yes |
√ |
√ |
√ |
√ |
|
|
PC-9 |
Yes |
√ |
√ |
√ |
√ |
|
|
H3255 |
Yes |
√ |
√ |
√ |
√ |
|
|
|
||||||
|
Validation |
H358 |
Yes |
√ |
√ |
√ |
|
|
H460 |
No |
√ |
√ |
√ |
√ |
|
|
H1975 |
No |
√ |
||||
|
K562 |
No |
√ |
√ |
√ |
√ |
|
|
A431 |
Yes |
√ |
√ |
√ |
||
|
|
||||||
|
% Correct |
80% |
80% |
90% |
90% |
||
|
|
||||||
|
Predictions of EGFR TKI sensitivity are denoted for ten cell lines used in training/validation. Column 2 demonstrates experimental sensitivity to an EGFR TKI, erlotinib (Table 1). Column 3 demonstrates prediction of sensitivity using mutational status of EGFR. Columns 4–6 denote prediction of sensitivity of the cell lines using the 10, 50, and 180 gene signatures in DLDA. √: denotes correct prediction based on experimental sensitivity to EGFR TKI. *: Leave-a-group-out cross-validation incorrectly predicts 3 of 8 replicates of this cell line. |
||||||
|
Balko et al. BMC Genomics 2006 7:289 doi:10.1186/1471-2164-7-289 |
||||||
